Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for Acute Myeloid Leukemia in First Morphological Remission

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 2, 2015, Pages 373-378

  Walter, Roland B ^a,b,c   Sandmaier, Brenda M ^a,b   Storer, Barry E ^a   Godwin, Colin D ^b   Buckley, Sarah A ^c   Pagel, John M ^a,b   Sorror, Mohamed L ^a,b   Deeg, H Joachim ^a,b   Storb, Rainer ^a,b   Appelbaum, Frederick R ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Acute myeloid leukemia; Hematopoietic cell transplantation; Minimal residual disease; Morphological remission; Prognostication

Indexed keywords

BUSULFAN; CALCINEURIN INHIBITOR; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE DERIVATIVE; FLUDARABINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THIOTEPA; TREOSULFAN; MYELOABLATIVE AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD CELL COUNT; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CONFIDENCE INTERVAL; CONSOLIDATION CHEMOTHERAPY; CORRELATION ANALYSIS; CYTOGENETICS; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG MEGADOSE; FEMALE; HAZARD RATIO; HUMAN; INDUCTION CHEMOTHERAPY; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; ADOLESCENT; ALLOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; PROGNOSIS; RECURRENT DISEASE; REMISSION; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING;

ADOLESCENT; ADULT; AGED; CONSOLIDATION CHEMOTHERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INDUCTION CHEMOTHERAPY; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84920895523     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.09.022     Document Type: Article

References (32)

1. Hamilton B.K., Copelan E.A. Concise review: the role of hematopoietic stem cell transplantation in the treatment of acute myeloid leukemia. Stem Cells 2012, 30:1581-1586.
2. Cornelissen J.J., Gratwohl A., Schlenk R.F., et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol 2012, 9:579-590.
3. Dominietto A. Minimal residual disease markers before and after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Curr Opin Hematol 2011, 18:381-387.
4. Buccisano F., Maurillo L., Del Principe M.I., et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 2012, 119:332-341.
5. Buckley S.A., Appelbaum F.R., Walter R.B. Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia. Bone Marrow Transplant 2013, 48:630-641.
6. Hourigan C.S., Karp J.E. Minimal residual disease in acute myeloid leukaemia. Nat Rev Clin Oncol 2013, 10:460-471.
7. Bostrom B., Brunning R.D., McGlave P., et al. Bone marrow transplantation for acute nonlymphocytic leukemia in first remission: analysis of prognostic factors. Blood 1985, 65:1191-1196.
8. McGlave P.B., Haake R.J., Bostrom B.C., et al. Allogeneic bone marrow transplantation for acute nonlymphocytic leukemia in first remission. Blood 1988, 72:1512-1517.
9. Keating S., Suciu S., de Witte T., et al. Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial. The European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto (GIMEMA) Leukemia Cooperative Groups. Bone Marrow Transplant 1996, 17:993-1001.
10. Kern W., Haferlach T., Schoch C., et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 2003, 101:64-70.
11. Ogawa H., Ikegame K., Kawakami M., et al. Impact of cytogenetics on outcome of stem cell transplantation for acute myeloid leukemia in first remission: a large-scale retrospective analysis of data from the Japan Society for Hematopoietic Cell Transplantation. Int J Hematol 2004, 79:495-500.
12. Kim D.H., Sohn S.K., Kim J.G., et al. Parameters for predicting allogeneic PBSCT outcome of acute myeloid leukemia: cytogenetics at presentation versus disease status at transplantation. Ann Hematol 2005, 84:25-32.
13. Walter R.B., Pagel J.M., Gooley T.A., et al. Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission. Leukemia 2010, 24:1276-1282.
14. Wheatley K., Burnett A.K., Goldstone A.H., et al. Asimple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 1999, 107:69-79.
15. Rowe J.M., Kim H.T., Cassileth P.A., et al. Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group. Cancer 2010, 116:5012-5021.
16. Walter R.B., Gooley T.A., Wood B.L., et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. JClin Oncol 2011, 29:1190-1197.
17. Walter R.B., Buckley S.A., Pagel J.M., et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood 2013, 122:1813-1821.
18. Walter R.B., Gyurkocza B., Storer B.E., et al. Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. Leukemia 2015, 29:137-144.
19. Vardiman J.W., Thiele J., Arber D.A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951.
20. Grimwade D., Hills R.K., Moorman A.V., et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010, 116:354-365.
21. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
22. Sorror M.L., Giralt S., Sandmaier B.M., et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 2007, 110:4606-4613.
23. Döhner H., Estey E.H., Amadori S., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
24. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
25. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
26. Gianfaldoni G., Mannelli F., Baccini M., et al. Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study. Br J Haematol 2006, 134:54-57.
27. Elliott M.A., Litzow M.R., Letendre L.L., et al. Early peripheral blood blastclearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. Blood 2007, 110:4172-4174.
28. Gianfaldoni G., Mannelli F., Bencini S., et al. Peripheral blood blast clearance during induction therapy in acute myeloid leukemia. Blood 2008, 111:1746-1747.
29. Lacombe F., Arnoulet C., Maynadie M., et al. Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study. Leukemia 2009, 23:350-357.
30. Arellano M., Pakkala S., Langston A., et al. Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia. Cancer 2012, 118:5278-5282.
31. Vainstein V., Buckley S.A., Shukron O., et al. Rapid rate of peripheral blood blast clearance accurately predicts complete remission in acute myeloid leukemia. Leukemia 2014, 28:713-716.
32. Loken M.R., Alonzo T.A., Pardo L., et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood 2012, 120:1581-1588.